If you smoke and want to quit, call the national quit line at 1-800-784-8669 to speak with a confidential coach. In what ...
SurvivorNet on MSN
Targeted therapy in a shot: New approval for EGFR-mutated lung cancer can improve day-to-day life for patients
Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...
Lung cancer patients receiving immunochemotherapy earlier in the day had a 52% lower risk of progression in a new medical ...
The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...
Daiichi Sankyo Company ($DSKYF) announced an update on their ongoing clinical study. Daiichi Sankyo and Merck Launch New Lung Cancer Study With ...
Trethera Corp. received a $2.7M NIH grant to study combining TRE-515 with KRAS inhibitors for lung cancer. Learn how this ...
The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and ...
Small cell lung cancer (SCLC) often responds well to initial treatment before later relapsing. Researchers are continuing to investigate new treatments, such as targeted therapy and immunotherapy ...
Retevmo (selpercatinib) is a medicine that is used in adults for certain types of non-small-cell lung cancer (NSCLC) that have a certain fusion in a gene known as receptor tyrosine kinase (RET). This ...
The decision to end the programme comes 18 months after Genmab's former partner for the acasunlimab, BioNTech, pulled out of ...
Wendy Brooks, a survivor of extensive-stage small cell lung cancer, and her husband and care partner, Larry Brooks, spoke ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback